Skip to content
LATEST
Health

Immunic keeps Phase 3 MS readout on track for December 2026

The company says ENSURE-1 and ENSURE-2 randomized 2,221 patients as it prepares a possible U.S. New Drug Application.

Immunic keeps Phase 3 MS readout on track for December 2026

Immunic said on Nov. 13 in an SEC filing that its two fully enrolled Phase 3 ENSURE trials of vidofludimus calcium in relapsing multiple sclerosis remain on track for December 2026 data.

The readout is the company’s main near-term regulatory milestone: ENSURE-1 randomized 1,121 patients and ENSURE-2 randomized 1,100, and Immunic said positive results would support a potential U.S. New Drug Application in mid-2027.

“As we approach the top-line data from our Phase 3 ENSURE trials in relapsing multiple sclerosis (MS) in December, we believe Immunic is entering one of the most important periods in its history,” Erik Lundgren, Immunic’s chief executive, said in the company release filed with the SEC.

Vidofludimus calcium is being tested as an oral therapy for multiple sclerosis, a neurologic disease in which inflammatory and neurodegenerative processes can contribute to disability. Immunic said the ENSURE trials are running at more than 100 sites in 15 countries.

The company also said initiation activities are under way for PROTECT-MS, a Phase 3 trial in progressive multiple sclerosis. Immunic expects first patient enrollment in that study in the first half of 2027.

The filing tied the clinical timelines to preparation for a possible commercial transition. Immunic appointed Jaa Roberson as chief people officer effective Oct. 19, 2026, and Chitrang Davé as chief data and digital officer effective Sept. 1, 2026. The company said both newly created roles support regulatory and commercial readiness.

Immunic also reported third-quarter operating expenses of $43.4 million for the period ended Sept. 30, 2026. Research and development expenses were $23.9 million for the quarter, up from $20.0 million in the same period of 2025, with the increase attributed in part to personnel costs, drug supply and NDA readiness activities.

The company’s supporting evidence for progressive MS remains earlier and less definitive than the pending Phase 3 relapsing MS data. Immunic said new Phase 2 CALLIPER analyses showed favorable disability trends during an open-label extension, but the extension was not placebo-controlled and included only patients who chose to continue treatment.

Other data presented at MSToronto2026 included preclinical findings and post-hoc analyses. Immunic said the clinical relevance of the preclinical findings has not been established, and that two proposed statistical methods used in a post-hoc CALLIPER analysis have not been validated or accepted by regulators.

Immunic said it expects ENSURE top-line data in December 2026, potential U.S. NDA submission in mid-2027 if results are positive, first PROTECT-MS enrollment in the first half of 2027 and a targeted potential regulatory approval date in 2028.

Source: SEC filing, Immunic, Nov. 13, 2026.

Atlas360 reports health research and does not provide medical advice.

More stories

Latest news